DK0897726T3 - Antipruritisk middel - Google Patents

Antipruritisk middel

Info

Publication number
DK0897726T3
DK0897726T3 DK97912539T DK97912539T DK0897726T3 DK 0897726 T3 DK0897726 T3 DK 0897726T3 DK 97912539 T DK97912539 T DK 97912539T DK 97912539 T DK97912539 T DK 97912539T DK 0897726 T3 DK0897726 T3 DK 0897726T3
Authority
DK
Denmark
Prior art keywords
antipruritic agent
antipruritic
morphinian
opiate
derivatives
Prior art date
Application number
DK97912539T
Other languages
English (en)
Inventor
Hiroshi Nagase
Jun Utsumi
Takashi Endoh
Toshiaki Tanaka
Junzo Kamei
Kuniaki Kawamura
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18041771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0897726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of DK0897726T3 publication Critical patent/DK0897726T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Record Carriers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Elimination Of Static Electricity (AREA)
  • Table Equipment (AREA)
  • Steroid Compounds (AREA)
DK97912539T 1996-11-25 1997-11-21 Antipruritisk middel DK0897726T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP31347696 1996-11-25
PCT/JP1997/004267 WO1998023290A1 (en) 1996-11-25 1997-11-21 Antipruritic agent

Publications (1)

Publication Number Publication Date
DK0897726T3 true DK0897726T3 (da) 2007-08-13

Family

ID=18041771

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97912539T DK0897726T3 (da) 1996-11-25 1997-11-21 Antipruritisk middel

Country Status (15)

Country Link
US (2) US6174891B1 (da)
EP (5) EP1310255B1 (da)
KR (1) KR100557801B1 (da)
CN (3) CN1535687A (da)
AT (3) ATE359076T1 (da)
AU (1) AU738743B2 (da)
CA (1) CA2244256C (da)
DE (3) DE69732868T2 (da)
DK (1) DK0897726T3 (da)
ES (3) ES2215158T3 (da)
NO (1) NO316309B1 (da)
NZ (1) NZ331001A (da)
PT (1) PT897726E (da)
TW (1) TW542838B (da)
WO (1) WO1998023290A1 (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763445A (en) * 1996-03-08 1998-06-09 Adolor Corporation Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith
WO1998027985A1 (en) * 1996-12-24 1998-07-02 Elkhoury George F Topical application of opioid drugs such as morphine for relief of itching and skin disease or irritation
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
JP3211027B2 (ja) * 1998-11-13 2001-09-25 丸石製薬株式会社 カプサイシン含有外用剤
WO2001014382A1 (en) * 1999-08-23 2001-03-01 Toray Industries, Inc. Analgesics containing as the active ingredient quaternary ammonium salt derivatives of morphinan
DE60039444D1 (de) 1999-08-24 2008-08-21 Toray Industries Heilmittel für neuropathischen schmerz und versuchstier-modelle des neuropathischen schmerzes
WO2001074819A1 (en) * 2000-04-03 2001-10-11 Toray Industries, Inc. Analgesics containing morphinan n-oxide derivatives as the active ingredient
JP2002249442A (ja) * 2001-02-21 2002-09-06 Fumakilla Ltd アレルギー減感作治療薬
CA2442423C (en) 2001-03-30 2009-11-03 Toray Industries, Inc. Therapeutic drug for psychoneurotic disorders
US6617308B2 (en) 2001-04-30 2003-09-09 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
US7294688B2 (en) 2001-04-30 2007-11-13 Nanogen Inc. Biopolymer marker indicative of disease state having a molecular weight of 1348 daltons
EP1402899A4 (en) * 2001-05-08 2009-03-11 Toray Industries MEANS FOR THE TREATMENT OF SEPSIS
US6844438B2 (en) 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
CA2464528A1 (en) * 2001-11-02 2003-05-15 Elan Corporation, Plc Pharmaceutical composition
NZ535987A (en) 2002-03-29 2006-08-31 Santen Pharmaceutical Co Ltd k-opioid receptor agonist comprising 2-henylbenzothiazoline derivative
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
ES2286461T3 (es) * 2002-09-25 2007-12-01 Euro-Celtique S.A. Hidroformas n-substituidss y uso de las mismas.
CA2561509C (en) 2004-03-30 2012-08-28 Toray Industries, Inc. Anti-itching agent
US7704522B2 (en) * 2004-09-08 2010-04-27 Clyde Morgan Topical medicament
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2580694A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US7453122B2 (en) * 2005-02-08 2008-11-18 Taiwan Semiconductor Manufacturing Co., Ltd. SOI MOSFET device with reduced polysilicon loading on active area
PT1870413E (pt) * 2005-03-10 2013-10-01 Toray Industries Agente antiprurítico para o pruridro provocado pela esclerose múltipla
BRPI0608671B1 (pt) * 2005-04-06 2022-07-19 Toray Industries, Inc Processos para produzir um cristal de forma a de cloridrato de 17-ciclopropilmetil-3,14 b-diidróxi-4,5a-epóxi-6b-[n-metil-trans-3-(3-furil)-acril amido]-morfinano
AU2006313137B2 (en) * 2005-11-09 2013-01-17 Toray Industries, Inc. Therapeutic or prophylactic agent for functional bowel disorder
WO2007072749A1 (ja) * 2005-12-21 2007-06-28 Toray Industries, Inc. 鎮咳剤
NZ575620A (en) * 2006-09-20 2010-11-26 Mallinckrodt Inc Preparation of substituted morphinan-6-ones and salts and intermediates thereof
US9040726B2 (en) 2007-03-06 2015-05-26 Mallinckrodt Llc Process for the preparation of quaternary N-alkyl morphinan alkaloid salts
EP2137189B1 (en) * 2007-03-06 2015-05-06 Mallinckrodt LLC Process for the preparation of quaternary n-alkyl morphinan alkaloid salts
WO2008133297A1 (ja) 2007-04-24 2008-11-06 Toray Industries, Inc. ジスキネジアの治療または予防剤
JP5099127B2 (ja) * 2007-04-26 2012-12-12 東レ株式会社 ４，５−エポキシモルヒナン誘導体を含有する安定な固形製剤
EP2168580B1 (en) * 2007-06-22 2015-12-02 Toray Industries, Inc. Remedy or preventive for schizophrenia
MX2010003660A (es) * 2007-10-05 2010-08-10 Toray Industries Agente para aliviar problemas de la piel que comprende un derivado de morfinano o una sal de adicion de acido, farmacologicamente aceptable del mismo como ingrediente activo.
WO2009138734A2 (en) * 2008-05-14 2009-11-19 Serentis Limited Use of opioid compounds in peripheral pain, wound healing and scar formation
EP2285780B1 (en) * 2008-05-27 2015-08-26 Mallinckrodt LLC Processes and compounds for the preparation of normorphinans
US9458109B2 (en) 2008-09-03 2016-10-04 Mallinckrodt Llc Substituted berbines and processes for their synthesis
WO2010096790A1 (en) * 2009-02-23 2010-08-26 Mallinckrodt Inc. (+)-morphinananium n-oxides and processes for their production
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
US8436174B2 (en) * 2009-02-23 2013-05-07 Mallinckrodt Llc (+)-morphinanium quaternary salts and processes for their production
JP2012518652A (ja) * 2009-02-23 2012-08-16 マリンクロッド インコーポレイテッド （＋）−６−ヒドロキシ−モルフィナンまたは（＋）−６−アミノ−モルフィナン誘導体
WO2011009020A2 (en) 2009-07-16 2011-01-20 Mallinckrodt Inc. Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
MX362830B (es) 2010-01-29 2019-02-14 Toray Industries Agente terapeutico o profilactico para enfermedades del tracto biliar.
ES2586655T3 (es) 2011-01-31 2016-10-18 Toray Industries, Inc. (-)-17-(ciclopropilmetil)-3,14beta-dihidroxi-4,5alfa-epoxi-6beta-[N-metil-trans-3-(3-furil)acrilamido]morfinano para su utilización en el tratamiento o prevención de la caquexia por cáncer
CN103917543A (zh) 2011-09-08 2014-07-09 马林克罗特有限公司 在不分离中间体的情况下制备生物碱
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
ES2984559T3 (es) * 2012-12-14 2024-10-29 Trevi Therapeutics Inc Métodos de tratamiento del prurito
WO2016052617A1 (ja) * 2014-09-30 2016-04-07 国立大学法人筑波大学 ナルフラフィン含有局所適用製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN106866688B (zh) * 2015-12-10 2019-05-03 山东诚创医药技术开发有限公司 一种纳呋拉啡的精制方法
KR20180120756A (ko) * 2016-03-21 2018-11-06 트레비 테라퓨틱스, 인코포레이티드 요독증성 소양증의 치료
CN108883185B (zh) * 2016-12-06 2021-10-08 江苏恒瑞医药股份有限公司 一种κ阿片受体激动剂在制备治疗法尼醇X受体激动剂引起的瘙痒的药物中的用途
HUE069820T2 (hu) 2018-03-08 2025-04-28 Victoria Link Ltd Nalfurafin alkalmazása demielinizációs betegségek kezelésére
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
EP3950059A4 (en) * 2019-03-29 2023-01-11 Nippon Chemiphar Co., Ltd. USE OF A T-TYPE CALCIUM CHANNEL BLOCKER TO TREAT PRURITUS
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
TWI893157B (zh) 2020-06-30 2025-08-11 日商東麗股份有限公司 具有嗎啡喃骨架之化合物或其藥理學上可容許之酸加成鹽的用途
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer
WO2025095039A1 (ja) * 2023-10-31 2025-05-08 ティア・リサーチ・コンサルティング合同会社 皮膚疾患の医薬組成物、及び医薬品の新規用途探索方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU196376B (en) * 1985-05-23 1988-11-28 Sandoz Ag Process for preparing morphinane derivatives and pharmaceutical compositions containing such compounds
US5021413B1 (en) * 1988-08-24 1994-12-13 Sankyo Co Analgesic thiomorpholins, their preparation, and pharmaceutical compositions containing them
EP0398720A3 (en) * 1989-05-18 1991-07-03 Glaxo Group Limited Piperazine derivatives
US6323212B1 (en) * 1992-01-23 2001-11-27 Toray Industries, Inc. Morphinan derivative and its pharmaceutical applications
JPH06122677A (ja) * 1992-08-28 1994-05-06 Sankyo Co Ltd 光学活性なカルボン酸アミド誘導体
EP0657163B1 (en) * 1993-06-30 1998-10-14 Toray Industries, Inc. Antitussive
JPH09504018A (ja) * 1993-10-20 1997-04-22 ザ ブーツ カンパニー ピーエルシー 抗掻痒薬としてのイブプロフェンおよびフルルビプロフェン
IT1273751B (it) 1994-02-11 1997-07-10 Smithkline Beecham Farma Derivati azaciclici
CA2288828A1 (en) * 1997-07-14 1999-01-28 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith
US5760023A (en) 1997-07-14 1998-06-02 Adolor Corporation Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith

Also Published As

Publication number Publication date
ES2215158T3 (es) 2004-10-01
CN1214634A (zh) 1999-04-21
EP1310255A1 (en) 2003-05-14
NO983431L (no) 1998-09-24
CA2244256A1 (en) 1998-06-04
NZ331001A (en) 2000-05-26
ATE291429T1 (de) 2005-04-15
EP1327444B1 (en) 2005-03-23
ATE263563T1 (de) 2004-04-15
AU4968397A (en) 1998-06-22
CA2244256C (en) 2006-07-11
DE69737592T2 (de) 2008-01-03
KR100557801B1 (ko) 2006-04-21
ES2285733T3 (es) 2007-11-16
US6174891B1 (en) 2001-01-16
EP0897726B1 (en) 2007-04-11
CN1180844C (zh) 2004-12-22
DE69732868T2 (de) 2006-04-13
ATE359076T1 (de) 2007-05-15
DE69728585T2 (de) 2004-08-05
ES2236630T3 (es) 2005-07-16
EP1310255B1 (en) 2004-04-07
DE69737592D1 (de) 2007-05-24
EP1327444A1 (en) 2003-07-16
EP0897726A1 (en) 1999-02-24
DE69732868D1 (de) 2005-04-28
JP3531170B2 (ja) 2004-05-24
AU738743B2 (en) 2001-09-27
CN1530111A (zh) 2004-09-22
NO316309B1 (no) 2004-01-12
DE69728585D1 (de) 2004-05-13
EP1310251A1 (en) 2003-05-14
PT897726E (pt) 2007-07-09
EP0897726A4 (en) 2003-05-28
WO1998023290A1 (en) 1998-06-04
TW542838B (en) 2003-07-21
CN1535687A (zh) 2004-10-13
CN1291717C (zh) 2006-12-27
EP1312361A1 (en) 2003-05-21
US6316461B1 (en) 2001-11-13
KR19990081978A (ko) 1999-11-15
NO983431D0 (no) 1998-07-24

Similar Documents

Publication Publication Date Title
NO983431L (no) Anti-klöemidler
AR020442A1 (es) Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
ES2184127T3 (es) Derivados de sulfamato anticonvulsivos utiles para el tratamiento de la obesidad.
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
ID18883A (id) Pesaing 5-ht 1f
WO2003048301A3 (en) Anti-hla-dr antibodies and the methods of using thereof
DE69935670D1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
CY1105980T1 (el) Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
BR9608594B1 (pt) misturas de benzimidazóis substituìdos para o combate de protozoários parasìticos.
PT1282418E (pt) Utilizacao de derivados pirazolo para o tratamento da infertilidade
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
EA200000522A1 (ru) 5-htагонисты
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
NO20005548L (no) Mykobakterieinhibitorer
EA200100182A1 (ru) Лечение состояний тревожности
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
IT1289154B1 (it) Derivati di isoflavone loro preparazione e loro impiego terapeutico
MX9602767A (es) Dimaleato de n,n-dietil-8,8-dipropil-2-azaspiro[4,5]decano-2-propanamina.
MXPA04004757A (es) Uso de una ascomicina para el tratamiento de blefaritis.